Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal IDJP (Indonesian Journal of Pharmaceutics)
Miki Takenaka
1. Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebbashi 371-8511, Japan 2. Department of Pharmacy, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi 371-8511, Japan

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
The Impact of Sunitinib N-oxide as a Photodegradation Product of Sunitinib Miki Takenaka; Yuta Takahashi; Hideaki Yashima; Takuya Araki; Koujirou Yamamoto
Indonesian Journal of Pharmaceutics Vol 1, Issue 1, Jan - April 2019
Publisher : Universitas Padjadjaran (Unpad)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1286.684 KB) | DOI: 10.24198/idjp.v1i1.19908

Abstract

During treatment with sunitinib, dosage adjustment according to the monitored blood concentration of sunitinib and SU12662 is considered useful. On the other hand, the appearance of hand-foot skin reaction (HFSR) cannot be explained by blood sunitinib concentration alone. Although light exposure greatly affects skin disorders associated with medication use, the photodegradation of sunitinib has not been studied in detail. Here, we investigated the photodegradation products of sunitinib using LC-MS and examined cytotoxic activities using an MTT assay. N-desethyl sunitinib and sunitinib N-oxide were identified as photodegradation products, and their concentrations increased under irradiation in a time-dependent manner. Although the IC50 value of N-desethyl sunitinib in the HEK 293 cell line (11.6 µmol/L) was similar to that of sunitinib (8.6 µmol/L), the IC50 value of sunitinib N-oxide (121.9 µmol/L) was over 10 times higher than that of sunitinib. In addition, N-desethyl sunitinib and sunitinib N-oxide were found in blood obtained from a patient taking sunitinib (24.7 and 2.3 ng/mL, respectively). Because the appearance of adverse drug reactions associated with sunitinib can be reduced by using α-tocopherol nicotinate, which has a strong antioxidant effect, we believe that sunitinib N-oxide might strongly promote the development of HFSR.Keyword : sunitinib, sunitinib N-oxide, photodegradation product, light
Co-Authors Hideaki Yashima Koujirou Yamamoto Takuya Araki Yuta Takahashi